$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
普拉替尼(Pralsetinib)的副作用和不良反应
2025-10-19 11:44:20
Check Details
普拉替尼(Pralsetinib)的中文说明书
2025-10-19 11:44:20
Check Details
靶向药奥希替尼(Osimertinib),泰瑞沙,Tagrisso的详细说明书
2025-10-19 11:44:20
Check Details
靶向药奥希替尼(Osimertinib)的中文说明书
2025-10-19 11:44:20
Check Details
奥希替尼(Osimertinib)的副作用:严重不良反应,常见副作用,副作用管理
2025-10-19 11:44:20
Check Details
奥希替尼(Osimertinib)的用法用量:用药指南,剂量调整,特殊人群用药,用药注意事项
2025-10-19 11:44:20
Check Details
FDA批准奥希替尼(Osimertinib)作为EGFR突变非小细胞肺癌的一线治疗药物
2025-10-19 11:44:20
Check Details
FDA批准奥希替尼(Osimertinib)用于治疗EGFRT790M突变阳性非小细胞肺癌
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)的副作用如何缓解
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)是治疗什么疾病的
2025-10-19 11:44:20
Check Details
西米普利单抗(Cemiplimab)的注意事项和药物相互作用
2025-10-19 11:44:20
Check Details
宗格替尼(Zongertinib)的功效与作用
2025-10-19 11:44:20
Check Details
1
2
...
2960
2961
2962
2963
2964
2965
2966
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
3
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
4
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
5
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
6
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
7
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
8
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
9
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor